Huahai Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | 600521 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600521PeersSector | |
|---|---|---|---|---|
P/E Ratio | 72.8x | 21.3x | −0.4x | |
PEG Ratio | −1.09 | 0.18 | 0.00 | |
Price/Book | 2.8x | 2.3x | 2.6x | |
Price / LTM Sales | 3.2x | 2.5x | 3.1x | |
Upside (Analyst Target) | 5.0% | 29.9% | 47.5% | |
Fair Value Upside | Unlock | 17.5% | 5.9% | Unlock |
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade services. Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989 and is headquartered in Linhai, China.